<DOC>
	<DOCNO>NCT00678769</DOCNO>
	<brief_summary>This phase I trial study side effect best dose cixutumumab temsirolimus treat patient locally advanced metastatic cancer . Monoclonal antibody , cixutumumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Temsirolimus may stop growth cancer cell block enzymes need cell growth . Giving cixutumumab together temsirolimus may kill cancer cell .</brief_summary>
	<brief_title>Cixutumumab Temsirolimus Treating Patients With Locally Advanced Metastatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate safety tolerability ; determine maximum tolerate dose ( MTD ) combination IMC-A12 ( cixutumumab ) temsirolimus patient without biopsiable advanced cancer . II . To evaluate biologic effect individual drug drug combination expression/phosphorylation potential marker response patient biopsiable disease . III . To assess tumor metabolism positron emission tomography ( PET ) . SECONDARY OBJECTIVES : I . To report clinical tumor response combination descriptive fashion . OUTLINE : DOSE ESCALATION PHASE : Patients receive temsirolimus intravenously ( IV ) 30 minute cixutumumab IV 60 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After MTD determine , subsequent patient enrol MTD expansion cohort . MTD EXPANSION COHORT : Patients assign 1 3 treatment group . GROUP A : Patients receive temsirolimus IV 30 minute day 15 22 course 1 day 1 , 8 , 15 , 22 subsequent course . Patients also receive cixutumumab IV 60 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . GROUP B : Patients receive cixutumumab IV 60 minute day 15 22 course 1 day 1 , 8 , 15 , 22 subsequent course . Patients also receive temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . GROUP C : Patients receive temsirolimus IV 30 minute cixutumumab IV 60 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow within 30 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients advance metastatic cancer Patients enrol expansion cohort may antidiabetic treatment , baseline glucose = &lt; 120 All patient must sign informed consent indicate aware investigational nature study ; patient must also sign authorization release protect health information Patients allow unlimited prior treatment Patients must register MD Anderson Cancer Center ( MDACC ) institutional database ( CORE ) prior treatment study drug Estimated life expectancy great 3 month Patients must â‰¥ 4 week beyond treatment chemotherapy , investigational therapy , biological , targeted agent radiotherapy , must recover = &lt; grade 1 toxicity previous baseline toxicity ; exception : patient must &gt; = 6 week beyond treatment monoclonal antibody ; patient may receive palliative low dose radiotherapy limbs 14 week therapy provide pelvis , sternum , scapula , vertebra , skull include radiotherapy field Patients must &gt; = 2 week beyond treatment hormonal therapy Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 Absolute neutrophil count &gt; = 1500/mL Platelets &gt; = 100,000/mL Creatinine = &lt; 2 X upper limit normal ( ULN ) Total ( T. ) bilirubin = &lt; 1.5 X ULN Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) and/or alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 5 X ULN Women childbearing potential MUST negative serum urine human chorionic gonadotropin ( HCG ) test unless prior hysterectomy menopause ( defined 12 consecutive month without menstrual activity ) ; patient become pregnant breastfeed study ; sexually active patient must agree use contraception prior study entry , duration study participation , 3 month last dose Patients must &gt; = 16 year age ; patient Ewing 's Sarcoma must &gt; = 14 year age Patients may receive investigational agent Patients pregnant breastfeeding Patients history abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day Patients uncontrolled intercurrent illness include , limited , active infection require hospitalization Patients history hypersensitivity monoclonal antibody treatment immunosuppressant agent Patients history cerebrovascular accident ( CVA ) , myocardial infarction unstable angina within previous six month start therapy Patients New York Heart Association class III great congestive heart failure uncontrolled hyperlipidemia ( cholesterol &gt; 300 mg/dl ; triglyceride 2.5 X ULN despite lipid lower agent ) Patients fast blood sugar &gt; 120 ; patient oral hypoglycemic agent insulin exclude ; exception : patient expansion cohort may antidiabetic treatment ( include hypoglycemic agent and/or insulin ) control Patients drug strong P450 cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inhibitors inducer ; drug stop 5 halflives prior start investigational agent temsirolimus ; strong inducing inhibit agent restart 1 week end study treatment ; principal investigator ( PI ) designee go over/check list medication individual patient ; NOTE : Physiologic replacement steroid ( either prednisone hydrocortisone ) patient adrenalectomy allowed Patients history brain metastasis eligible , however brain metastasis treat ( treatment define surgery radiation therapy [ RT ] ) patient free symptoms/signs steroid least 3 month study entry Patients highly aggressive lymphoma ( i.e . Burkitt 's )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>